Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

283

Figures (1-1)

Tables (1-7)

Sum=495

Publishing Process of This Article

Item

Count

Browse

Download

Sum=40

Apr 24, 2025 (publication date) through Apr 27, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Oncol. Apr 24, 2025; 16(4): 104827
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.104827

Table 1 Detailed characteristics of patients recruited in the study

Characteristic	Details	Concomitant medications
Total number of patients	10
Gender	6 females, 4 males
Mean age	65 years
Age range	50-80 years
Cancer types	Lung cancer: 4 patients (40%)	Cisplatin; Paclitaxel; Ondansetron; Dexamethasone; Diclofenac
	Breast cancer: 3 patients (30%)	Doxorubicin; Cyclophosphamide; Zolendronic acid; Letrozole;Anastrozole; Dexamethasone; Diclofenac
	Prostate cancer: 2 patients (20%)	Leuprolide; Enzalutamide; Zolendronic acid; Diclofenac
	Pancreatic cancer: 1 patient (10%)	Gemcitabine; 5-Fluorouracil; Dexamethasone; Diclofenac

Citation: Chakraborty P, Borgohain M. Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series. World J Clin Oncol 2025; 16(4): 104827
URL: https://www.wjgnet.com/2218-4333/full/v16/i4/104827.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i4.104827